Deferoxamine

A reversible S-phase inhibitor of human lymphocyte proliferation

Howard M Lederman, A. Cohen, J. W W Lee

Research output: Contribution to journalArticle

Abstract

Deferoxamine is widely used therapeutically as a chelator of ferric ion in disorders of iron overload. This study demonstrates that this drug is a potent inhibitor of DNA synthesis by human B and T lymphocytes in vitro, but has relatively little effect on the synthesis of RNA and protein. The inhibitory effects of deferoxamine are completely reversible by washing or by adding stoichiometric amounts of Fe3+. Micromolar concentrations of deferoxamine decrease intracellular levels of deoxyribonucleoside triphosphates, which is similar to the effects of hydroxyurea. The binding of iron by deferoxamine likely causes an inhibition of ribonucleotide reductase activity, thereby preventing cells from completing the S phase of the cell proliferation cycle. As a reversible and nontoxic S-phase inhibitor, it may have important experimental and therapeutic applications.

Original languageEnglish (US)
Pages (from-to)748-753
Number of pages6
JournalBlood
Volume64
Issue number3
StatePublished - 1984
Externally publishedYes

Fingerprint

Deferoxamine
Lymphocytes
S Phase
Iron
Deoxyribonucleosides
Nucleic Acid Synthesis Inhibitors
Ribonucleotide Reductases
Iron Overload
Hydroxyurea
T-cells
Cell proliferation
Chelating Agents
Washing
Cell Cycle
B-Lymphocytes
Cell Proliferation
RNA
Ions
T-Lymphocytes
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Hematology

Cite this

Deferoxamine : A reversible S-phase inhibitor of human lymphocyte proliferation. / Lederman, Howard M; Cohen, A.; Lee, J. W W.

In: Blood, Vol. 64, No. 3, 1984, p. 748-753.

Research output: Contribution to journalArticle

Lederman, Howard M ; Cohen, A. ; Lee, J. W W. / Deferoxamine : A reversible S-phase inhibitor of human lymphocyte proliferation. In: Blood. 1984 ; Vol. 64, No. 3. pp. 748-753.
@article{1d69afa4d1b745c7b63871300277a19b,
title = "Deferoxamine: A reversible S-phase inhibitor of human lymphocyte proliferation",
abstract = "Deferoxamine is widely used therapeutically as a chelator of ferric ion in disorders of iron overload. This study demonstrates that this drug is a potent inhibitor of DNA synthesis by human B and T lymphocytes in vitro, but has relatively little effect on the synthesis of RNA and protein. The inhibitory effects of deferoxamine are completely reversible by washing or by adding stoichiometric amounts of Fe3+. Micromolar concentrations of deferoxamine decrease intracellular levels of deoxyribonucleoside triphosphates, which is similar to the effects of hydroxyurea. The binding of iron by deferoxamine likely causes an inhibition of ribonucleotide reductase activity, thereby preventing cells from completing the S phase of the cell proliferation cycle. As a reversible and nontoxic S-phase inhibitor, it may have important experimental and therapeutic applications.",
author = "Lederman, {Howard M} and A. Cohen and Lee, {J. W W}",
year = "1984",
language = "English (US)",
volume = "64",
pages = "748--753",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "3",

}

TY - JOUR

T1 - Deferoxamine

T2 - A reversible S-phase inhibitor of human lymphocyte proliferation

AU - Lederman, Howard M

AU - Cohen, A.

AU - Lee, J. W W

PY - 1984

Y1 - 1984

N2 - Deferoxamine is widely used therapeutically as a chelator of ferric ion in disorders of iron overload. This study demonstrates that this drug is a potent inhibitor of DNA synthesis by human B and T lymphocytes in vitro, but has relatively little effect on the synthesis of RNA and protein. The inhibitory effects of deferoxamine are completely reversible by washing or by adding stoichiometric amounts of Fe3+. Micromolar concentrations of deferoxamine decrease intracellular levels of deoxyribonucleoside triphosphates, which is similar to the effects of hydroxyurea. The binding of iron by deferoxamine likely causes an inhibition of ribonucleotide reductase activity, thereby preventing cells from completing the S phase of the cell proliferation cycle. As a reversible and nontoxic S-phase inhibitor, it may have important experimental and therapeutic applications.

AB - Deferoxamine is widely used therapeutically as a chelator of ferric ion in disorders of iron overload. This study demonstrates that this drug is a potent inhibitor of DNA synthesis by human B and T lymphocytes in vitro, but has relatively little effect on the synthesis of RNA and protein. The inhibitory effects of deferoxamine are completely reversible by washing or by adding stoichiometric amounts of Fe3+. Micromolar concentrations of deferoxamine decrease intracellular levels of deoxyribonucleoside triphosphates, which is similar to the effects of hydroxyurea. The binding of iron by deferoxamine likely causes an inhibition of ribonucleotide reductase activity, thereby preventing cells from completing the S phase of the cell proliferation cycle. As a reversible and nontoxic S-phase inhibitor, it may have important experimental and therapeutic applications.

UR - http://www.scopus.com/inward/record.url?scp=0021259518&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021259518&partnerID=8YFLogxK

M3 - Article

VL - 64

SP - 748

EP - 753

JO - Blood

JF - Blood

SN - 0006-4971

IS - 3

ER -